Plain-English translation of NCT07294625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new treatment called LVIVO-TaVec200 for people with multiple myeloma — a blood cancer — that has come back or stopped responding to previous treatments. Researchers want to understand how safe this medication is, how well patients tolerate it, and whether it can help shrink the cancer. The trial will enroll about 36 patients and follow them for approximately 2 years.
Multiple myeloma can become resistant to standard treatments, leaving patients with few good options. This medication represents a new approach designed to help people whose cancer has already failed at least three previous treatment regimens.
You likely qualify if…
You likely don't qualify if…
You would receive a single infusion of the treatment at your assigned dose level. The study includes a screening visit, possible bridging therapy if needed, the treatment itself, and follow-up visits to monitor your safety and response over approximately 2 years. Researchers will track how your body responds, measure any side effects, and test whether the cancer shrinks.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China